Anacetrapib是一种选择性 CETP 抑制剂，作用于 rhCETP 和 C13S CETP 突变体的 IC50 分别为 7.9 nM 和 11.8 nM，能够增加 HDL-C、降低 LDL-C，不影响醛固酮和血压。

Evacetrapib是一种强效且选择性的 CETP 抑制剂，IC50 为 5.5 nM。

CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.

Torcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma.

BMS 795311 is a potent cholesteryl ester transfer protein (CETP) inhibitor with IC50 of 4 nM.

Dalcetrapib is a rhCETP inhibitor with IC50 of 0.2 μM.

Obicetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors substantially increase the concentration of high-density lipoprotein cholesterol (HDL-C), which may have a possible beneficial effect for cardiovascular disease risk reduction.